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Hiroaki Okayasu*, Takahiro Shinozaki†, Akira Osone†, Yuji Ozeki† and Kazutaka Shimoda†Abstract
Background: Cases of acute pancreatitis caused by sodium valproate (VPA) have been reported by many authors
thus far. However, most of these were cases with epilepsy. Chronic renal failure is also regarded as a risk factor for
acute pancreatitis. Here, we report a case of acute pancreatitis development due to VPA in a patient with bipolar
disorder on hemodialysis for chronic renal failure.
Case presentation: The patient was a 52-year-old Japanese male who was diagnosed as bipolar disorder on
hemodialysis for renal failure. He was treated with VPA and manic symptoms gradually stabilized. However, the
patient complained of severe abdominal pain. Blood amylase was found to be markedly high, and computed
tomography revealed pancreatomegaly and an increased amount of peripancreatic fat. Hence, we diagnosed the
case as acute pancreatitis caused by VPA. We discontinued oral medication, and he was started on a pancreatic
enzyme inhibitor, antibiotics, and transfusion, and he showed improvement.
Conclusion: It has been reported that acute pancreatitis induced by VPA is caused by intermediate metabolites of
VPA. We consider that patients with renal failure are prone to pancreatitis caused by VPA because of the
accumulation of these intermediate metabolites. We need close monitoring for serious adverse effects such as
pancreatitis when we prescribe VPA to patients with bipolar disorder on hemodialysis for chronic renal failure,
although VPA is safer than other mood stabilizers.
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stabilizerBackground
Acute pancreatitis is a rare, but serious and sometimes
fatal, side effect of sodium valproate (VPA) administration.
Hemodialysis for the treatment of chronic renal failure is
also regarded as a risk factor for acute pancreatitis [1].
Here, we report our experience of a patient with bipolar
disorder who developed acute pancreatitis caused by VPA
administration while undergoing hemodialysis.
Case presentation
The patient was a 52-year-old man who had proteinuria
and hematuria that were diagnosed in his high-school* Correspondence: hokayasu@dokkyomed.ac.jp
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unless otherwise stated.days but for which he had not sought treatment. He sub-
sequently experienced severe renal failure due to nephro-
sclerosis and was started on hemodialysis 2 years before
this case report. Thereafter, he had a depressive mood,
anxiety, and insomnia, and he subsequently presented
with symptoms such as pressure of speech, flight of ideas,
delusions of grandeur, thought dispersion, and irritability.
Diagnosis was bipolar disorder according to DSM-IV-TR
diagnostic criteria, and he was treated with olanzapine but
showed no improvement. He was admitted to the psychi-
atric ward of our university hospital.
Because the patient continued to show a threatening
attitude and irritability toward medical staff or other
patients while being hospitalized, he was initially treatedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Abdominal computed tomography showing
pancreatomegaly and an increased amount of
peripancreatic fat.
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http://www.biomedcentral.com/1471-244X/14/93with VPA (400 mg/day) in addition to olanzapine (10 mg/
day) and zopiclone (5 mg/day) and other drugs for gen-
eral medical conditions [nifedipine(40 mg/day), artino-
lol hydrochloride (20 mg/day), valsartan (160 mg/day)
and doxazosin mesilate (3 mg/day) for hypertension, and
sodium polystyrene sulfonate (25 g/day) for hyperpotasse-
mia, allopurinol (100 mg/day) for hyperuricemia and
alfacalcidol (0.25 μg/day) for chronic renal failure] by
the previous physician in charge. The dosage of VPA was
increased up to 1,200 mg/day, and the manic symp-
toms gradually stabilized. The plasma level of VPA was
88.5 μg/ml.
However, approximately 3 weeks after increasing the
dose of VPA to 1,200 mg (62 days after admission), the
patient complained of severe abdominal pain. Blood
amylase was found to be markedly high at 1,227 U/l
(pancreatic amylase: 1,133 U/l) (Table 1), and abdominal
computed tomography revealed pancreatomegaly and an
increased amount of peripancreatic fat (Figure 1). Hence,
acute pancreatitis was diagnosed. We believe that the
pancreatitis was due to VPA because olanzapine, zopi-
clone and other drugs for general medical conditions
had shown no particular adverse effects, and the patient
had not consumed alcohol and did not have a history of
biliary system disease such as gallstones. We promptly
discontinued oral medication, and he was started on a
pancreatic enzyme inhibitor, antibiotics, and transfusion,
and he showed improvement for approximately 1 month
(Figure 2). Because the patient’s psychiatric symptoms
were exacerbated, levomepromazine (50 mg/day) was
then started without any adverse effects. He was dis-
charged on Day 197 of the illness.Table 1 Laboratory data at the time when acute pancreatitis














Abbreviations: AST, aspartate transaminase; ALT, alanine transaminase; ALP, alkaline
urea nitrogen; Cre, creatinine; Na, sodium; K, potassium; Cl, chloride; CK, creatine kin
C-reactive protein; WBC, white blood cells; NEUTRO, neutrophil; EOSINO, eosinophil
Hb, hemoglobin; Ht, hematocrit; Plt, platelets.
Numbers in bold type indicate abnormal value.Discussion
In 1979, Canfield et al. [2] and Batalden et al. [3] separ-
ately reported cases of acute pancreatitis caused by VPA.
Since then, more than 100 such cases have appeared in
the literature [4], although most cases involved epi-
lepsy, and only two cases involved bipolar disorder
[5,6]. Ng et al. reported a female patient with epilepsy
who was administered VPA and developed pancrea-
titis during hemodialysis [7]. Since then, the similar
types of cases that have been reported thus far were
cases with epilepsy [1,8-10]. To the best of our knowledge,
the present report is the first case of VPA-induced pan-
creatitis in a patient with bipolar disorder who was also
undergoing hemodialysis.was diagnosed










RBC 373 × 104/mm3
Hb 11.4 g/dl
Ht 35.8%
Plt 11.9 × 104/mm3
phosphatase; γ-GTP, γ-glutamyl transpeptidase; T-Bil, total bilirubin; BUN, blood
ase; AMY, amylase; P-AMY, pancreatic-type amylase; Glu, glucose; CRP,
; BASO, basophil; Moc, monocyte; LYMPHO, lymphocyte; RBC, red blood cells;
Figure 2 The course of treatment with VPA and changes in
serum amylase. Abbreviations: AMY, amylase; P-AMY, pancreatic-
type amylase; VPA, sodium valproate.
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lites of VPA have toxic effects on pancreatic cells, and
this is believed to be the main cause of VPA-induced
pancreatitis [11], although the definite metabolite has
not been revealed yet. VPA is primarily metabolized as a
glucuronic acid-conjugated compound [10]; however,
several types of intermediate metabolites other than the
glucuronic acid-conjugated compound are found in nor-
mal human urine. One possible etiology is that patients
with renal failure are prone to pancreatitis because these
intermediate metabolites accumulate due to renal failure
leading to pancreatic cell damage.
When considering regimens of other mood stabilizers
for patients with bipolar disorder who have renal failure,
lithium carbonate does not bind to the plasma protein,
and more than 95% of lithium is excreted by the kidney
[12]. Therefore, patients with renal dysfunction would be
expected to accumulate lithium and show a decline in
renal function and serious lithium toxicity. In addition,
maintaining adequate blood levels of lithium to achieve a
response may be difficult because of the high dialyzabil-
ity of lithium [13]. For administration of carbamaze-
pine (CBZ), close monitoring of patients with renal failure
is believed to be required because toxicity can readily occur
as a result of accumulation of toxic CBZ-hydroxylated me-
tabolites due to low albuminemia and inhibition of CBZ
binding to the serum protein by a uremic toxin [14]. There-
fore, using other mood stabilizers such as these for patients
on hemodialysis requires close therapeutic drug monitor-
ing. Physicians should be alert to signs of serious toxicity
and the onset of adverse effects.
VPA is primarily metabolized by the liver; therefore,
the management of the dose and blood level should berelatively easy because of its low dialyzability [15].
Therefore, VPA seems to be safe even for patients on
hemodialysis. However, as in the present case, we must
be cognizant of the possibility of serious adverse effects
such as pancreatitis.
Conclusion
When prescribing a mood stabilizer to patients with bi-
polar disorder on hemodialysis, VPA is believed to be
safer than other mood stabilizers. However, it is neces-
sary to monitor patients closely for serious adverse ef-
fects such as pancreatitis.
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